UnitedHealth Group Incorporated is a health care company operating in the United States and internationally. It operates through four segments: Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare. Optum Health provides care delivery, care management, wellness and consumer engagement, and health financial services. Optum Insight offers software and information products, advisory consulting, and managed services outsourcing. Optum Rx provides pharmacy care services and programs. UnitedHealthcare offers consumer-oriented health benefit plans and services, as well as Medicaid plans and other federal, state, and community health care programs. The company was founded in 1974 and is based in Eden Prairie, Minnesota.
UnitedHealth's AI Turnaround and Regulatory Wins Offset Medicare Membership Losses
▲
UnitedHealth settles FTC insulin pricing case UnitedHealth's OptumRx and Emisar Pharma reached a settlement with the FTC over insulin pricing allegations, removing a major legal cloud. This reduces regulatory uncertainty and potential fines, which supports the stock price by lowering risk.
This is a new positive regulatory development that directly removes a legal overhang for UNH.
▲
UnitedHealth invests $3 billion in AI to cut costs UnitedHealth plans to spend $3 billion on AI across 2026-2027, expecting nearly $1 billion in cost savings this year. The technology already returns $2 for every $1 spent, which could boost profit margins and support the stock.
This is a new, concrete capital allocation and technology initiative that could improve UNH's profitability.
▼
Berkshire and Tepper exit UNH amid Medicare membership losses Berkshire Hathaway fully exited and David Tepper cut his stake in UNH during Q1 2026. The company lost 965,000 Medicare Advantage members and plans to drop 2.3-2.8 million more from unprofitable contracts, signaling demand weakness and raising concerns about future revenue.
This new disclosure of high-profile investor exits and large membership losses directly pressures UNH's stock.
◆
CMS star rating recalculation offers limited benefit CMS is recalculating 2026 Medicare Advantage star ratings after a lawsuit, but only for plans that improve. UnitedHealthcare could gain $500 million if broad criteria applied, but current approach yields little change, leaving uncertainty about the actual financial impact.
This new regulatory development could affect UNH's Medicare bonuses, but the outcome is uncertain.
Latest
▲2▼2
UNH's profit recovery stalls as commercial costs stay high; AI and TPG deals offer support
▼
Commercial cost trend delays margin recovery past 2027 UNH's commercial medical cost trend is running above 11%, pushing full margin recovery past 2027. Management said the No Surprises Act dispute process adds 50 basis points of extra cost in 2026, now at least 100 basis points. Higher costs mean less profit from each premium dollar, weighing on the stock.
This is the core reason UNH's profit turnaround is taking longer than expected, directly pressuring the stock.
▼
IRS transfer pricing scrutiny could raise tax bill The IRS is challenging how UNH priced transactions with a foreign subsidiary and proposes sizable tax adjustments across multiple years. If applied, taxable income and tax owed would rise. UNH plans to contest, but the uncertainty can weigh on the stock until resolved.
A new regulatory threat that could reduce future profits and adds uncertainty, a fresh negative for UNH.
▲
UNH sells Optum Florida stake to TPG, focuses on turnaround UNH sold an interest in its Florida Optum Health operations to private equity firm TPG. The deal lets that business grow faster while UNH focuses on its broader turnaround. Management now expects Optum Health margins around 2% this year, rising to 4% in 2027 and 6% after, supporting the stock.
A concrete step to fix the troubled Optum Health unit and improve margins, a positive driver for UNH.
▲
UNH invests $1.5B in AI to boost Optum Insight UNH plans to invest nearly $1.5 billion in AI in 2026, with a third for software products. Early tools show a 96% first-pass approval rate for digital prior authorization and a 17% pharmacy cost reduction for customers. Optum Insight revenue hit $5.4 billion with margins improving, a growth driver for the stock.
Shows a new technology push that could improve efficiency and growth, a positive for UNH's outlook.
Q3 2026
▲2▼2
UnitedHealth Q3: Earnings Beat, Medicare Bonuses, But Cost and Legal Risks Linger
▲
Q2 Earnings Beat and Raised Guidance UnitedHealth's Q2 adjusted EPS of $6.38 beat expectations, and the company raised full-year guidance to $19.50–$20.00. The medical care ratio improved to 83.9%, showing better cost control. This signals stronger profitability and supports the stock.
Earnings beat and guidance raise are key positive drivers for the stock.
▲
Medicare Advantage Bonuses and Capital Returns UnitedHealth received $3.9 billion in Medicare Advantage bonuses, passed an external HouseCalls audit, expanded buybacks by at least $5 billion, and raised its dividend. These actions boost investor confidence and return cash to shareholders.
Bonuses and capital returns are new positive developments that affect shareholder value.
▼
Rising Commercial Medical Costs Delay Margin Recovery Commercial medical costs above 11% are delaying margin recovery past 2027. This means the company's profitability may remain under pressure longer than expected, which could weigh on the stock.
This is a new negative factor that impacts future profitability.
▼
Expanding Legal and Regulatory Risks The DOJ expanded its antitrust probe into Claritev, a $3.6 billion Part D subsidy expiration pressures 2027 premiums, Senator Warren's breakup bill threatens Optum, and investor lawsuits over governance and the Change Healthcare breach continue. IRS transfer pricing scrutiny could raise taxes.
These legal and regulatory issues create uncertainty and potential financial penalties.
News & notes movingUNH
United States
UNH
UnitedHealth Group Shares Gain 1.83% Ahead of October 13 Earnings Report
UnitedHealth Group closed at $371.90, up 1.83% and ahead of the S&P 500's 0.73% gain, as investors look toward the insurer's October 13, 2026 earnings disclosure. Analysts expect earnings per share of $4.12, a 41.1% rise from the same quarter a year earlier, while revenue is projected at $111.38 billion, down 1.57% year over year. For the full year, the Zacks Consensus Estimates forecast earnings of $19.85 per share and revenue of $446.78 billion, changes of +21.41% and -0.18% respectively. The stock carries a Zacks Rank of #2 (Buy) and trades at a forward P/E of 18.4, a discount to the industry average of 21.25, with a PEG ratio of 1.37. The Medical - HMOs industry holds a Zacks Industry Rank of 21, placing it in the top 9% of more than 250 industries.
UNH · Capital · Neutral Shares rose ahead of the Oct 13 earnings report, with analysts expecting EPS of $4.12 (+41.1% YoY) but revenue down 1.57%; Zacks Rank #2 and forward P/E discount are valuation context.
Raymond James Adds Xencor, Calyxt, UnitedHealth to October Healthcare Top Picks
Raymond James has updated its Healthcare Top Picks list for October, adding Xencor, Calyxt, and UnitedHealth Group while removing Relay Therapeutics, Tyra Biosciences, and Oscar Health. Xencor replaces Relay Therapeutics, with the firm anticipating significant interest in Xencor's dataset at ESMO at the end of October and seeing near-term upside on a positive readout and a clear path to pivotal development for XmAb819 in clear cell renal cell carcinoma, even as it maintains a Strong Buy rating on Relay Therapeutics. Calyxt replaces Tyra Biosciences, with Raymond James citing an increasingly derisked setup for both of Calyxt's lead assets, CLYM116 and budoprutug; initial Phase 2 data for CLYM116 is expected next year ahead of a Phase 3 study in IgAN patients, while additional budoprutug data across pMN, ITP, and SLE is due in the fourth quarter of 2026, and the firm noted the subcutaneous formulation could differentiate it from approved anti-CD19 Uplizna. UnitedHealth Group replaces Oscar Health ahead of third-quarter earnings in mid-October, with the firm saying the recent pullback on Stars and midterm election-related concerns creates an attractive setup into what it expects to be a strong quarter. Raymond James said it remains positive on Oscar Health with an Outperform rating but currently prefers UnitedHealth given the monthly nature of the list.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Capital
UNH · Capital · Positive Added to Raymond James' Healthcare Top Picks ahead of Q3 earnings, with the recent Stars-related pullback seen as an attractive setup.
XNCR · Capital · Positive Added to Raymond James' Healthcare Top Picks on anticipated ESMO dataset interest and near-term upside from an XmAb819 readout.
OSCR · Capital · Neutral Raymond James remains positive with an Outperform rating but removed Oscar Health from the Top Picks list in favor of UnitedHealth.
RLAY · Capital · Neutral Removed from the Top Picks list, though Raymond James maintains its Strong Buy rating on Relay Therapeutics.
TYRA · Capital · Neutral Removed from the Top Picks list as Calyxt replaces Tyra Biosciences; no company-specific development cited.
Humana Shrinks Medicare Advantage Footprint for 2027
Humana will offer Medicare Advantage plans in nearly 2,600 counties across 45 states and Washington, D.C. for the 2027 plan year, a sharp reduction from the 46 states and Washington, D.C. it covered for 2026, when its plans reached 85% of U.S. counties. The Louisville, Kentucky-based insurer, the second-largest MA player behind UnitedHealth, said the new footprint represents more than 80% of U.S. counties, and it has announced plans to discontinue offerings affecting 600,000 enrollees. UnitedHealth said its UnitedHealthcare MA plans will remain accessible to 94% of Medicare-eligible individuals next year, unchanged from 2026, though Bloomberg reported that roughly 390,000 people will be part of plans being shut down. CVS Health's Aetna unit and Centene are also pulling back their MA offerings, according to CMS data reviewed by Wall Street analysts, while Alignment Healthcare is expanding to 55 counties and Clover Health said its plans will reach 5.2M Medicare-eligible individuals across 203 counties in five states. The moves come as the MA market contends with rising medical costs and intense government scrutiny, and after CMS said 2027 MA enrollment is expected to reach 34M, a 6% decline, despite a more than 16% drop in MA premiums versus 2026 on a weighted average basis.
HUM · Regulation · Negative Humana is sharply shrinking its 2027 Medicare Advantage footprint and discontinuing plans affecting 600,000 enrollees amid rising costs and government scrutiny.
ALHC · Demand · Positive Alignment Healthcare is expanding its Medicare Advantage footprint to 55 counties, a growth move against peers' pullbacks.
CLOV · Demand · Positive Clover Health said its plans will reach 5.2M Medicare-eligible individuals across 203 counties in five states, an expansion.
CNC · Regulation · Negative Centene is pulling back its Medicare Advantage offerings amid rising medical costs and intense government scrutiny.
CVS · Regulation · Negative CVS Health's Aetna unit is pulling back its Medicare Advantage offerings amid rising medical costs and government scrutiny.
UNH · Regulation · Neutral UnitedHealth's MA plans stay at 94% coverage unchanged, but ~390,000 enrollees are in plans being shut down amid MA market scrutiny and rising costs.
UnitedHealth Group Names Robert Hunter President of UnitedHealthcare
UnitedHealth Group has appointed Robert Hunter as president of UnitedHealthcare as part of a leadership realignment. The new UnitedHealthcare chief is expected to help advance a multi-year plan focused on margin recovery and modernization of operations, with a remit that includes restoring confidence among regulators and customers while sharpening the business's digital experience across key insurance offerings. The company also added Jodee Kozlak as chief administrative officer, moves that point to execution on margin recovery while technology and AI programs target G&A savings. UnitedHealth Group, a US-based healthcare operator with a market value of about $339.1 billion, runs insurance and health-benefits operations in the United States and internationally. The cleanest check on whether the leadership reset is working will be how reported segment margins and medical cost trends at UnitedHealthcare and Optum move through 2027, especially in Medicare and Medicaid where management already flagged pressure on profitability.
UNH · Capital · Neutral UnitedHealth names Robert Hunter president of UnitedHealthcare as part of a leadership realignment aimed at margin recovery and operational modernization.
UnitedHealth Group announced that Jodee Kozlak has joined the company as chief administrative officer, a newly created role overseeing People, Real Estate, Procurement and Corporate Security to support enterprise modernization and alignment across the business. Kozlak previously led global expansion at Alibaba and human resources at Target, and has served on the boards of C.H. Robinson Worldwide and KB Home. The appointment signals a greater emphasis on organizational efficiency and large-scale transformation as UnitedHealth works to restore margins through plan exits and pricing resets. The hire follows the company's Q2 2026 earnings, which showed improved operating earnings even as revenue growth stayed muted. UnitedHealth's narrative projects $498.6 billion in revenue and $23.5 billion in earnings by 2029, requiring 3.5% yearly revenue growth and about a $9.4 billion earnings increase from $14.1 billion today.
UNH · Capital · Neutral UnitedHealth creates a new chief administrative officer role to support enterprise modernization and margin restoration, a leadership/organizational change with no clear directional impact.
UnitedHealth Earns Zacks Rank #2 as Earnings Estimates Hold Steady
UnitedHealth Group holds a Zacks Rank #2 (Buy), with consensus estimates pointing to earnings of $4.03 per share for the current quarter, a year-over-year change of +38%. The Zacks Consensus Estimate for the quarter remained unchanged over the last 30 days, while the $19.82 consensus for the current fiscal year, indicating a year-over-year change of +21.2%, has moved +0.6% over the same period. For the next fiscal year, the consensus estimate of $22.54 implies a change of +13.7%, having risen +0.5% over the past month. Revenue consensus stands at $111.38 billion for the current quarter, a year-over-year change of -1.6%, with $446.78 billion and $458.33 billion expected for the current and next fiscal years, changes of -0.2% and +2.6% respectively. In the last reported quarter, UnitedHealth posted revenues of $112.03 billion, up +0.4% year over year, and EPS of $6.38 versus $4.08 a year earlier, beating the consensus revenue estimate of $110.12 billion by +1.74% and the EPS estimate by +29.15%. The stock carries a Zacks Value Style Score of B, indicating it trades at a discount to its peers.
UNH · Capital · Positive UnitedHealth holds a Zacks Rank #2 (Buy) with steady-to-rising consensus EPS estimates and a Value Style Score of B, an analyst-valuation signal.
UnitedHealth's turnaround is proceeding largely on plan, but commercial health plan medical costs are running modestly above the 11% the company had been expecting, while Medicare costs are tracking below its roughly 10% estimate for 2026 and Medicaid trend is broadly in line. Management credits benefit design, care management, network curation and a lighter respiratory season for Medicare landing below plan, and attributes the commercial overrun to the independent resolution process under the No Surprises Act, which it calls ineffective. On its earnings call, management said IDR dispute awards contributed approximately 50 basis points of incremental medical cost trend in 2026 and now account for at least 100 basis points of total cost, with roughly 60% of all arbitration cases brought by just five entities and average payouts to out-of-network providers now 11 times what Medicare would pay. The elevated trend has pushed the timeframe for full commercial margin recovery past 2027, which management calls a delay rather than a setback, and it still expects Medicaid margins to stay pressured for 2026. UnitedHealth lifted 2026 adjusted earnings per share guidance to $19.50 to $20 and reaffirmed its 13%-16% long-term growth rate, though its operating margin over the last twelve months, at 4.8%, remains below its three-year average of 7.1%.
UNH · Capital · Positive UnitedHealth lifted 2026 adjusted EPS guidance to $19.50-$20 and reaffirmed its 13%-16% long-term growth rate.
UNH · Regulation · Negative No Surprises Act IDR arbitration awards added ~50bp to 2026 medical cost trend and pushed full commercial margin recovery past 2027.
UnitedHealth Sells TPG Stake in Florida WellMed Clinics to Aid Optum Turnaround
UnitedHealth Group has sold an interest in some of its Optum Health operations in Florida to private-equity firm TPG, specifically involving its WellMed clinics that focus heavily on older patients. The company's CFO said the move is not about raising cash but about bringing in a partner that can provide local operating expertise and help the Florida business grow faster while UnitedHealth concentrates on its broader Optum Health turnaround. The timing is significant because Optum Health posted a negative operating margin in 2025 as medical costs rose and Medicare-related economics weakened, and UnitedHealth is now targeting an Optum Health margin of roughly 2% in 2026, 4% in 2027, and 6% in 2028. Optum says its Florida operations serve more than 240,000 patients across nearly 600 locations, and UnitedHealth is still opening roughly 15 clinics a year in Florida. The partnership does not eliminate the underlying pressures that caused Optum Health's problems: the division generated a $1.1 billion operating loss in 2025, compared with $6.9 billion of operating income the year before.
UNH · Capital · Neutral UnitedHealth sells a WellMed stake to TPG to bring local operating expertise and aid its Optum Health turnaround amid a $1.1B 2025 operating loss
TPG · Capital · Positive TPG acquires a stake in UnitedHealth's WellMed clinics, a private-equity deal for TPG
Elevance Tops UBS Benefits Survey as 77% of Employers Put Health Contracts Out to Bid
Elevance Health ranked as the highest-rated national health insurer in UBS's annual survey of employee-benefit managers, scoring 4.34 out of five, ahead of UnitedHealth Group at 4.23 and Kaiser Permanente at 4.20. UBS analysts led by A.J. Rice surveyed 166 benefits managers at companies with more than 100 employees, and found that about 77% of respondents plan to seek new proposals for all or a significant portion of their core medical benefits for 2027, up from 53% in last year's survey and 41% a year earlier. Aetna and Blue Cross Blue Shield plans outside Elevance had the greatest exposure to rebidding at 90%, followed by Cigna and Elevance, while UnitedHealth had the lowest exposure among the major carriers. Employers expect gross medical costs for self-insured plans to rise 7.9% in 2027, accelerating from an estimated 7% this year, with benefit design changes trimming about 0.3 percentage point to leave a net cost trend of approximately 7.5%. Among pharmacy-benefit managers, 92% of respondents said their PBM contracts are due for renewal in 2027 and about 65% plan to issue requests for proposals, more than double the 30% recorded last year, yet CVS Caremark, Cigna's Express Scripts and UnitedHealth's Optum Rx were the three most frequently cited as likely to improve their market positions. The survey also found that 91% of employers now cover newer obesity medicines, up from 52% last year, and UBS estimated that 19.1% of covered workers and dependents use GLP-1 medicines for obesity, a figure respondents expect to rise to 20.6% next year.
ELV · Competition · Positive Elevance ranked highest-rated national health insurer in UBS's benefits-manager survey, ahead of UnitedHealth and Kaiser.
UNH · Competition · Positive UnitedHealth had the lowest rebidding exposure among major carriers and its Optum Rx was cited as likely to improve its market position.
CI · Competition · Neutral Cigna has high rebidding exposure (90% for Aetna/BCBS, Cigna and Elevance next) but its Express Scripts PBM is cited as likely to improve its market position.
CVS · Competition · Positive CVS Caremark is one of the three PBMs most frequently cited as likely to improve market positions amid 2027 PBM contract renewals.
UnitedHealth sells Optum Florida stake to TPG as CooperCompanies cuts guidance and Amgen slides
UnitedHealth has sold an interest in some of its Optum Health operations in Florida to private equity firm TPG, part of the health conglomerate's effort to recover from a collapse in profits last year. CFO Wayne DeVeydt told Bloomberg News that Optum Health margins will be around 2% this year, above prior expectations, and should rise to around 4% in 2027 and 6% the following year. Amgen fell more than 8%, its worst single-day decline since 2016, after Novartis announced a Phase 3 trial failure for the heart disease therapy pelacarsen, which it is developing with Ionis Pharmaceuticals; BMO Capital Markets downgraded Amgen to Market Perform from Market Outperform with a $450 price target. CooperCompanies dropped 13% after issuing fiscal 2026 guidance below consensus, with revenue of $4.229B-$4.252B versus the prior $4.285B-$4.321B and non-GAAP diluted EPS of $4.51-$4.55 versus $4.58-$4.66 previously, and said its board decided to keep CooperSurgical rather than sell it while raising its share buyback authorization to $3B from $2B. Novo Nordisk fell more than 1% premarket after Morgan Stanley downgraded the stock to Underweight from Equal-weight, citing the semaglutide patent cliff, and the S&P 500 Health Care Sector Index slipped more than 3.5% for the week.
Biotech & Genomic Medicine › Cardiovascular & Heart-Failure Therapeutics ▼Technology
Biotech & Genomic Medicine › RNAi / Antisense Oligonucleotides ▼Technology
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▼Competition
AMGN · Capital · Negative BMO downgraded Amgen to Market Perform with a $450 price target after Novartis's pelacarsen Phase 3 failure.
COO · Capital · Negative CooperCompanies issued fiscal 2026 guidance below consensus and cut its EPS outlook.
UNH · Capital · Positive UnitedHealth sold an Optum Florida stake to TPG and guided Optum Health margins to ~2% this year, rising to ~4% in 2027 and 6% after, aiding its profit recovery.
IONS · Technology · Negative Novartis announced a Phase 3 trial failure for pelacarsen, which it is developing with Ionis Pharmaceuticals.
NVO · Capital · Negative Morgan Stanley downgraded Novo Nordisk to Underweight from Equal-weight, citing the semaglutide patent cliff.
MS · Capital · Negative Morgan Stanley downgraded Novo Nordisk to Underweight from Equal-weight.
UnitedHealth to Remove Prior Authorizations for 30% of Services by 2026
UnitedHealth Group's insurance unit, UnitedHealthcare, will eliminate prior-authorization requirements for a broad range of healthcare services starting October 1, as part of a plan to remove such requirements for 30% of services by the end of 2026. The changes span multiple specialties, including cardiology, genetic and laboratory testing, chiropractic care, physical and occupational therapy, speech therapy, orthopedics, and musculoskeletal procedures, and apply to commercial plans, Medicare Advantage, and individual ACA plans. UnitedHealthcare will also launch a rural prior-authorization waiver program on November 1 for eligible rural hospitals and affiliated providers, and is accelerating payments by up to 50% for approximately 1,400 rural hospitals during the third quarter. The company has not disclosed the financial impact, including potential administrative savings or effects on medical utilization, leaving the trade-off between simpler care and claims exposure unclear.
Brent tops $100, Treasury yields climb as U.S. equities slip
U.S. equities pushed lower on Wednesday as oil kept climbing, with Brent crude breaking above $100 a barrel while U.S.–Iran tensions in the Middle East continued to weigh on sentiment. Treasury yields advanced after the Treasury Department said it will repurchase up to $6 billion of longer-dated notes in Thursday's operation, tripling the size of its last long-end buyback; the 2-year yield rose 2 basis points to 4.42%, the 10-year added 5 basis points to 4.84%, and the 30-year gained about 4 basis points near 5.29%. Brent crude futures surged above $100 per barrel for the first time since July 24, with front-month Brent for November delivery climbing 3.3% to $101.13/bbl and Nymex crude jumping 3.2% to $96.02/bbl, as traffic through the Strait of Hormuz dropped from roughly 8 million barrels per day in late August to only 1 million barrels per day this week, according to Rystad Energy. Separately, Anthropic's Alignment Science Lead Evan Hubinger said he "earnestly" believes AI could kill all humans, putting his personal estimate of the probability at more than 10% within the next decade, and the company's latest risk report upgraded the risk from misalignment in high-stakes settings to "low" from "very low." Managed care stocks declined after CVS Health said at the Wells Fargo Healthcare Conference that it continues to face elevated medical costs, with notable decliners including UnitedHealth, Humana, Clover Health, Alignment Healthcare, Centene, Oscar Health, Elevance Health, and Molina Healthcare.
UnitedHealth to Invest $1.5B in AI to Boost Optum Insight
UnitedHealth Group is making artificial intelligence a bigger part of its strategy to strengthen Optum Insight's growth, planning to invest nearly $1.5 billion in AI-related initiatives in 2026, with about one-third earmarked for software products and platforms. The strategy is moving beyond experimentation into commercial products, expanding AI capabilities across autonomous coding, digital prior authorization, real-time payer-provider interfaces, and clinical quality and safety tools. Digital prior authorization is showing early traction, with AI achieving a 96% first-pass approval rate while retaining human review for cases not approved. Value Connect, another AI platform, has helped early customers achieve a 17% reduction in pharmacy costs. Optum Insight generated $5.4 billion in second-quarter 2026 revenues, with operating earnings up 13.6% year over year and margin improving to 25.3%. UnitedHealth trades at a forward price-to-earnings ratio of 18.48, above the industry average of 16.02, and carries a Zacks Rank #1 (Strong Buy).
Care Management Solutions Market to Grow from $22.56B to $42.62B by 2031
A new 375-page report from ResearchAndMarkets.com forecasts the global care management solutions market will grow from USD 22.56 billion in 2026 to USD 42.62 billion by 2031, a compound annual growth rate of 13.6%. The market's expansion is driven by the shift to value-based care, rising chronic disease prevalence, and adoption of AI-enabled platforms. Chronic care management led the market by application in 2025, while cloud-based solutions are expected to see the fastest growth. Asia Pacific is projected to record the highest CAGR, supported by digital health initiatives such as India's Ayushman Bharat Digital Mission, which linked over 100 crore health records by May 2026. Key players include Optum, Epic Systems, Oracle, Philips, and Veradigm.
Medicare Advantage Nonrenewal Notices Due October 2
Insurers have already told Wall Street which Medicare Advantage plans will end on December 31, 2026, but members will only learn by mail, with nonrenewal notices due by October 2. Humana confirmed that its 2027 plan exits will affect approximately 600,000 members, while UnitedHealth Group expects Medicare Advantage enrollment to decline by about 1.1 million. These terminations open a rare guaranteed-issue Medigap window, but only for members returning to Original Medicare, not for those switching to another Advantage plan. With Medicare Open Enrollment closing December 7, members should save the notice and price both coverage paths immediately, as Medigap premiums can range from $150 to $250 monthly, while a $0-premium Advantage plan may have an out-of-pocket maximum up to $9,250 in 2026.
UnitedHealth stock has gained about 41% since early March, trading near $400 a share, but the company's turnaround is incomplete: while Medicare and care-delivery margins improved, its commercial book deteriorated. Management now expects full margin recovery in the commercial segment to extend past 2027, with medical cost trend running above 11% and no signs of moderation. The company's overall operating margin stands at 4.8%, below its three-year average of 7.1%, and adjusted 2026 earnings guidance is $19.50 to $20 per share, with segment operating-earnings outlooks of at least $12 billion for UnitedHealthcare and at least $2.2 billion for Optum Health. Rivals also repriced, with Elevance Health up 41.6% and Cigna up 4.7% over the same period, but UnitedHealth's commercial cost trend has not yet turned.
UNH · Capital · Negative Commercial margin deterioration and delayed recovery past 2027, with medical cost trend above 11% and adjusted 2026 guidance below prior expectations.
The Villages Health Settles Medicare Fraud for $541.5 Million
The Justice Department announced a $541.5 million settlement with The Villages Health over alleged Medicare Advantage upcoding, resolving claims that from 2020 to 2024 the primary care provider submitted false diagnosis codes to increase reimbursements. By 2024, about half of the company's patient diagnosis codes were unsupported, according to an outside consultant's review cited by Healthcare Dive. The settlement targets the bankrupt pre-sale entity, The Villages Health System LLC, with the government holding a nondischargeable claim in the Chapter 11 process, while Humana's CenterWell division, which acquired the operating business for $68 million in late 2025, is shielded from direct payment. The insurers that received inflated payments, including Humana, UnitedHealthcare, and Blue Cross Blue Shield of Florida, are returning overpayments credited against the total. The same month, the Justice Department resolved two other Medicare Advantage upcoding cases, signaling a national enforcement priority on risk-adjustment fraud.
The Villages Health · Regulation · Negative The Villages Health System LLC settled DOJ Medicare Advantage upcoding claims for $541.5 million, with a nondischargeable claim in its Chapter 11 case.
HUM · Regulation · Neutral Humana's CenterWell unit acquired the operating business and is shielded from direct payment, but Humana received inflated payments and is returning overpayments credited against the settlement.
UNH · Regulation · Negative UnitedHealthcare received inflated Medicare Advantage payments and is returning overpayments credited against the $541.5M settlement.
Blue Cross Blue Shield of Florida · Regulation · Negative Blue Cross Blue Shield of Florida received inflated payments and is returning overpayments credited against the settlement.
Healthcare Costs to Rise 8.2% in 2027, Boosting MRSH, UNH, CNC
U.S. employers face another sharp increase in healthcare costs in 2027, with average health benefit costs per employee projected to climb 8.2% even after mitigation, according to a Marsh & McLennan survey of over 1,800 employers. Without cost-control measures, costs could rise about 11%, the steepest since 2003, driven by expensive treatments, GLP-1 weight-loss drugs, and AI-assisted billing. Aon echoes the warning, expecting a 9.5% rise before mitigation. This spending surge creates opportunities for benefits consultants like Marsh and insurers like UnitedHealth and Centene, which are positioned to help employers manage costs. Marsh and UnitedHealth carry a Zacks Rank #2, while Centene holds a #1 Strong Buy, with all three expected to see earnings growth in 2026 and 2027.
UnitedHealth Rises as 30% of Prior Approvals Head for Removal
UnitedHealth Group rose about 0.8% to $399.4 on Wednesday after announcing that, starting October 1, UnitedHealthcare will eliminate prior-authorization requirements for a broad range of conditions, including selected outpatient procedures, echocardiograms, therapies, and chiropractic care. This move brings the company closer to its commitment to scrap approvals for 30% of services that previously required them. The stakes are high: UnitedHealth's second-quarter results showed $112 billion in revenue but only $8 billion in operating earnings, a 7.1% operating margin. At $399.405, the stock trades 32.59% below its GF Value estimate of $592.48, but removing friction could also lead to heavier medical utilization, so the company must balance easier access with cost control.
UNH · Regulation · Neutral Removing prior-authorization requirements could improve customer satisfaction but may increase medical utilization, affecting costs.
Cigna Launches Smart Coverage to Bridge Health-Cost Gaps
Cigna Healthcare is introducing Medical with Smart Coverage, a new option for qualifying high-deductible health plans that provides eligible members up to $7,000 for covered injuries, illnesses, or hospitalizations, alongside Simple File Sync Plus, which automatically matches medical claims with supplemental benefits. The launch, set for January 1, 2027, initially targets U.S. clients with 500 to 2,999 employees, with broader availability in 2028. Citing a Cigna and Ipsos survey, nearly 60% of Americans are financially unprepared for a health event, and 44% have spent at least $1,000 out of pocket after a diagnosis. Cigna notes that employees are more than 2.5 times likelier to enroll in high-deductible plans when supplemental benefits are available. Competitors UnitedHealth Group and Elevance Health offer similar connected-benefits solutions, such as UnitedHealthcare's Benefit Ally and Anthem's Whole Health Connection.
UnitedHealth Commercial Cost Trend Delays Margin Recovery Past 2027
UnitedHealth's commercial medical cost trend is running modestly above 11%, pushing full commercial margin recovery past 2027. Management said the independent resolution process under the No Surprises Act is adding 50 basis points of incremental trend in 2026 and now totals at least 100 basis points of cost. The company raised adjusted earnings per share guidance for 2026 to a range of $19.50 to $20, and shares trade at $390.11. Medicare is improving, with the 2026 medical cost trend expected to come in below the initial estimate of around 10%, but management said the softer trend is not an inflection point. UnitedHealthcare expects full-year 2026 Medicare Advantage enrollment to decline by approximately 1.1 million through benefit adjustments and selective market participation changes.
UnitedHealth Group Faces IRS Transfer Pricing Scrutiny
UnitedHealth Group is facing IRS scrutiny over how it priced transactions with a foreign subsidiary, with the agency proposing sizable tax adjustments across multiple years. The IRS move focuses on transfer pricing and could significantly raise UnitedHealth Group's taxable income if the proposed changes are ultimately applied. UnitedHealth has said it plans to contest the proposed adjustments, keeping the timing and final financial impact uncertain for now. The company has a market cap of about $345.4b and a current profit margin of 3.1%, down from 5% last year. Investors will watch how UnitedHealth updates its tax exposure and provisions in upcoming filings, including whether its US$2.32 per share dividend for September 22, 2026 is adjusted.
UnitedHealth Prioritizes Medicare Advantage Profitability Over Membership Growth
UnitedHealth Group is shifting its Medicare Advantage strategy to prioritize profitability over membership expansion, expecting 2026 enrollment to decline by approximately 1.1 million members due to targeted exits from unprofitable plans. Medicare margins are now expected to finish the year above 3%, reflecting tighter benefit design, pricing actions, and a more favorable membership mix, while the company expects Medicare medical cost trends to come below the initial estimate of near 10%. UnitedHealth's consolidated medical care ratio improved to 86.7% in the second quarter from 89.4% a year ago, and the company raised its 2026 adjusted EPS outlook to $19.50-$20. The Zacks Consensus Estimate for UnitedHealth's 2026 earnings is pegged at $19.69 per share, implying 20.4% growth from the year-ago period, and the stock currently carries a Zacks Rank #1 (Strong Buy).
UNH · Capital · Positive UnitedHealth raised its 2026 EPS outlook and reported improved margins, signaling strong financial performance.
ELV · Competition · Negative UnitedHealth's strategic shift to prioritize profitability may pressure competitors like Elevance to follow suit, potentially impacting their growth.
HUM · Competition · Negative Humana faces competitive pressure as UnitedHealth exits unprofitable plans, potentially reshaping the market and affecting Humana's positioning.
Aon Forecasts 9.5% Rise in 2027 Employer Health Costs
Aon plc expects U.S. employer health-care costs to rise 9.5% in 2027, pushing average plan costs above $19,000 per employee. The forecast, based on its Health Value Initiative database covering more than 1,100 employers, 7.9 million employees and $135 billion of 2026 health-care spending, points to higher medical service use, chronic illness, expensive claims and prescription drugs, especially specialty medicines and GLP-1 therapies, as key drivers. Employers' average cost rose 8.8% in 2026 to $14,432 per employee, while employee payroll contributions increased 6.4% to $3,130, and Aon says employers now fund about 82% of total plan costs. The projected increase would mark a fourth straight year of employer health-cost growth close to double digits, with total plan costs up 8.3% in 2026 to $17,562 per employee. Aon's Health Solutions generated $818 million of second-quarter 2026 revenues and 5% organic growth, while Willis Towers Watson's Health business posted 8% organic growth in the same period, and UnitedHealth Group and Centene Corporation are managing medical costs through pricing and benefit design.
UnitedHealth Group Hit With Investor Lawsuit Over Governance And Cybersecurity Claims
UnitedHealth Group is facing a major investor lawsuit alleging longstanding corporate governance and cybersecurity failures tied to its Change Healthcare acquisition. The complaint claims oversight gaps at UnitedHealth contributed to what plaintiffs describe as the largest healthcare data breach in U.S. history. Investors argue that weaknesses in internal controls and board level risk management left sensitive patient and claims data exposed. The case raises fresh questions for shareholders about how UnitedHealth assesses, oversees, and discloses cybersecurity and acquisition related risks.
UnitedHealth Group has received a Zacks Rank of 1, or Strong Buy, driven by a 7.1% increase in the Zacks Consensus Estimate for current-year earnings over the past month to $19.69 per share. The stock also carries an average brokerage recommendation of 1.39 based on 27 analysts, with 20 Strong Buy and three Buy ratings. Zacks notes that brokerage recommendations often carry a positive bias, while its own rank is tied to earnings estimate revisions. The company's growing analyst optimism over earnings prospects could support near-term stock gains.
Health insurers drop Medicare Advantage plans affecting nearly 3 million seniors
Nearly 3 million older Americans face forced disenrollment from their Medicare Advantage plans this year as major insurers exit markets to protect profits. An analysis by Johns Hopkins Bloomberg School of Public Health researchers found one in 10 Medicare Advantage policyholders are losing their plans, up from a 6.9% disenrollment rate in 2025 and an average of 1% between 2018 and 2024. Humana announced it will exit multiple markets in 2027 for the second consecutive year, impacting 600,000 members, while Clear Spring Health shut down its Medicare Advantage operations effective June 1 and Presbyterian Health Plan will exit most markets in 2027 affecting about 30,000 policyholders. Insurers cite lower federal reimbursement rates and rising medical costs, with UnitedHealth and Humana together accounting for nearly half of all Medicare Advantage enrollment nationwide.
UnitedHealth Group Raises Dividend and Exits Medicare Advantage Plans
UnitedHealth Group's board authorized a cash dividend of US$2.32 per share payable September 22, 2026, while outlining further exits from certain Medicare Advantage plans and updated margin expectations. The company plans to exit plans covering more than 600,000 members and expects a 1.1 million enrollment decline by 2026, targeting Medicare margins above 3%. Management also raised its 2026 adjusted EPS outlook, supported by lower medical costs. The company projects $498.6 billion revenue and $23.5 billion earnings by 2029, requiring 3.5% yearly revenue growth and a roughly $9.4 billion earnings increase from $14.1 billion today.
Mangione Pleads Guilty in US Case Over Healthcare CEO Killing
Luigi Mangione pleaded guilty to federal stalking charges related to the fatal shooting of UnitedHealth Group Inc. executive Brian Thompson. He faces a maximum sentence of life in prison. The plea was entered in New York federal court Friday morning. Mangione also faces charges in New York state court.
UnitedHealth faces shareholder suit over governance failures
UnitedHealth Group is facing an amended shareholder lawsuit accusing the insurer of knowing about serious governance issues and doing little to ensure compliance, leading to significant losses in stock value. The suit was filed in a Minnesota federal court by the Employees’ Retirement System of the State of Rhode Island and Länsförsäkringar Fondförvaltning AB, a Swedish asset manager. Plaintiffs blame the board and senior company officers, alleging the company built its industry-leading earnings on a foundation of systemic wrongdoing and illegality, including defrauding the federal Medicare program, denying medically necessary care, deceiving a federal court, violating patient privacy laws, unlawfully suppressing competition, and manipulating earnings. The suit contends that defendants issued false and misleading statements in SEC filings, on earnings calls, and in four successive proxy statements, keeping the stock trading at artificially inflated prices while the company repurchased billions of dollars of its own shares. UnitedHealth reached an all-time closing high of $599.78 on November 11, 2024, and closed Wednesday at $405.59, after closing as low as $259.02 on March 27 of this year.
UnitedHealth's Lower Medical Costs Drive Earnings Recovery
UnitedHealth Group reported second-quarter results showing its medical care ratio fell to 86.7% from 89.4% a year ago, helping operating earnings rise 55% and prompting the company to raise its 2026 adjusted EPS guidance. The quarter included $860 million of favorable prior-period medical development, while commercial medical costs are increasing at a rate exceeding 11% due to higher provider billing and coding intensity and specialty drug costs. Elevance Health's second-quarter benefit expense ratio was 89.7%, up 80 basis points year over year, but the company raised its 2026 adjusted EPS guidance to at least $27. CVS Health's Aetna business benefited from lower medical costs in the second quarter, leading to an earnings beat and raised 2026 adjusted EPS guidance of $7.90 to $8.10. UnitedHealth shares have risen 47.9% in the past 12 months, and the stock trades at a forward price-to-earnings ratio of 18.83X compared with the industry average of 16.48X.
Pacira BioSciences reported second quarter 2026 total revenues of $192.4 million, a 6% increase over the prior year, and updated full-year guidance to $735 million to $760 million following the divestiture of iovera to Zimmer Biomet. EXPAREL net sales rose 3% to $147.8 million, ZILRETTA sales grew 4% to $32.6 million, and iovera sales increased 21% to $6.8 million. The company highlighted UnitedHealthcare's decision to provide separate reimbursement for EXPAREL outside the surgical bundle, bringing total covered lives to over 150 million, and noted that ZILRETTA was placed on UnitedHealthcare's preferred drug list. Pacira expects top-line data from three registrational studies later this year: the iovera spasticity study, the ZILRETTA shoulder osteoarthritis study, and Part A of the Phase 2 PCRX-201 study.
Elizabeth Warren pushes bill to break up UnitedHealth and CVS vertical integration
Senator Elizabeth Warren is pushing bipartisan legislation to force the breakup of vertically integrated healthcare giants like UnitedHealth Group and CVS Health, arguing their control over insurance, pharmacies, and providers drives up patient costs. The Patients Before Monopolies Act, reintroduced in May with Senator Josh Hawley, would ban common ownership of insurers and pharmacies and require divestiture within one year. Warren highlighted how UnitedHealth’s UnitedHealthcare and Optum units link insurance to pharmacy services, and said the same consolidation applies to CVS Health. The bill targets the three major pharmacy benefit managers—UnitedHealth, CVS Health, and Cigna—which supporters say control every link in the prescription drug delivery chain.
Companies defy macro uncertainty and raise guidance
A growing number of companies are raising their profit outlooks despite macroeconomic uncertainty. More S&P 500 firms are lifting guidance than cutting it, and Wall Street analysts have raised third-quarter earnings estimates for the index for the second consecutive quarter. Argus research analyst Christine Dooley views consistent guidance raises as a catalyst for market-beating returns. Among the companies that have raised guidance in the second quarter so far are Cheesecake Factory, Ford, General Motors, Hasbro, Starbucks, Coca-Cola, Charles Schwab, PayPal, US Bancorp, ASML, Seagate Technology, Supermicro Computer, Bristol Myers Squibb, Johnson & Johnson, UnitedHealth Group, 3M, Lockheed Martin, Northrop Grumman, United Airlines, and United Parcel Service.
Janus Henderson Forty Fund Says UnitedHealth Turnaround Is Ahead of Schedule
Janus Henderson Investors’ Forty Fund highlighted UnitedHealth Group as a top relative contributor in the second quarter of 2026, citing faster-than-expected progress on a turnaround plan led by returning former CEO Stephen Hemsley. The fund, which returned 19.00% for the quarter versus the Russell 1000 Growth Index’s 16.74%, said UnitedHealth exceeded its first-quarter earnings targets after announcing cost management, operational improvements, and margin expansion initiatives. The company has also disclosed significant AI investments aimed at boosting customer engagement and productivity. UnitedHealth shares closed at approximately $414.40 on July 31, 2026, giving it a market capitalization of about $378.61 billion.
Medicare Advantage Insurers Lock In 2027 Benefit Cuts and Market Exits
UnitedHealth and Humana have already locked in their 2027 Medicare Advantage strategies, with UnitedHealth trimming enrollment by 1.1 million members and Humana targeting 25% growth. Members whose plan is discontinued will have a 63-day guaranteed-issue window for Medigap Plans A, B, C, D, F, and G, though Plans C and F are unavailable to people newly eligible for Medicare on or after January 1, 2020. Missing that window allows insurers to medically underwrite, charge more, or deny coverage based on health. The Annual Notice of Change must arrive by September 30, and the Annual Enrollment Period runs from October 15 through December 7. CMS also grants a Special Enrollment Period from December 8 through the end of February for those whose plan does not renew.
UnitedHealth Group Fair Value Estimate Rises 12% After Q2 Analyst Target Increases
UnitedHealth Group's analyst fair value estimate has risen from $424.23 to $475.23, a 12% increase driven by Q2 earnings, Medicare Advantage and Optum Health updates, and refreshed 2026 earnings models. Several large firms raised price targets, with Wells Fargo moving from $485 to $526, Morgan Stanley from $468 to $529, and BofA from $475 to $512, citing better Medical Loss Ratio performance and Optum Health margin recovery. Revenue growth assumptions shifted from 3.12% to 3.47%, net profit margin from 4.43% to 4.71%, and future P/E multiple from 21.81x to 22.52x, while the discount rate remained near 7.11%. Bearish analysts flagged higher commercial costs and structural risks at Optum Health and Optum Insight, though near-term earnings risk is seen as more balanced.
UNH · Capital · Positive Analyst fair value estimate and price targets raised after Q2 earnings, Medicare Advantage and Optum Health updates, and refreshed 2026 models.
UnitedHealth's Q2 Cost Control and Raised Outlook Restore Investor Confidence
UnitedHealth Group reported second-quarter 2026 adjusted earnings of $6.38 per share, beating the Zacks Consensus Estimate of $4.94 and rising 56.4% year over year, while revenues edged up 0.4% to $112 billion. The adjusted medical care ratio improved to 86.7% from 89.4% a year earlier, reflecting stronger pricing and better cost management, and medical costs fell to $75.4 billion from $78.6 billion. Management raised its full-year 2026 adjusted earnings outlook to a range of $19.50 to $20 per share, marking the second consecutive quarter of guidance increases. The stock has gained 29.9% year to date, outperforming the industry's 25.8% growth and the S&P 500's 7.8% rise, though it now trades at a forward price-to-earnings multiple of 20.39 times, above its five-year median of 19.20 times. Despite ongoing regulatory scrutiny and expected membership declines, the company returned more than $13 billion to shareholders in 2025 through dividends and buybacks, and it currently carries a Zacks Rank of 1, or Strong Buy.
UnitedHealth Group commits $4 million to expand UT Health Sciences health hubs across Tennessee
UnitedHealth Group announced a $4 million commitment to expand the University of Tennessee Health Sciences' health hub network from five to 13 locations across Tennessee by the end of 2027. The funding, provided through the United Health Foundation with technical assistance from UnitedHealth Group, builds on nearly $2 million in support since 2022 and aims to reach 200,000 residents. The health hubs offer preventive care, chronic condition management, and health education in community settings, having already served more than 4,000 people through over 20,000 visits. The expansion is part of UnitedHealth Group's Communities of Health initiative, which launched with a $20 million commitment in 2026 to support community-based health models nationwide. The partnership will also strengthen rural health workforce pathways through collaborations with UT Health Sciences' nursing and medicine colleges.
Zacks Recommends 3M, Travelers, and UnitedHealth After Strong Q2 2026 Earnings
Zacks Investment Research recommends three Dow blue-chip stocks—3M, Travelers, and UnitedHealth Group—following their solid second-quarter 2026 earnings results. 3M raised its full-year adjusted earnings guidance to a range of $8.80 to $8.95 per share, up from $8.50 to $8.70 previously, and expects adjusted total revenue growth above 4.5%. Travelers reported a 14% increase in after-tax net investment income to $883 million and projects a full-year 2026 underwriting expense ratio of approximately 28.5%. UnitedHealth Group lifted its 2026 adjusted EPS outlook to between $19.50 and $20.00, up from more than $18.25, with revenues anticipated above $439 billion. Each stock carries a favorable Zacks Rank, with UnitedHealth at Strong Buy and the other two at Buy.
USA
